Back

Evaluating the eligibility for icosapent ethyl, and the barriers to its use within a novel cardiovascular disease secondary prevention nurse led clinic.

4 April 2025 (09:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Poster session (2) Secondary Prevention EAPC Premium Access ESC Preventive Cardiology 2025 European Association of Preventive Cardiology (EAPC)

About the speaker

Photo
Miss Holly Cousins

University Hospitals Dorset NHS Foundation Trust, Poole (United Kingdom of Great Britain & Northern Ireland)

87 More presentations in this session

Presentation thumbnail
Comparative efficacy and safety of antithrombotic regimens following left atrial appendage occlusion therapy in atrial fibrillation patients: a comprehensive Bayesian network meta-analysis
Doctor V. Lanari (Milan, IT)
Abstract Slides
Presentation thumbnail
Paroxysmal atrial fibrillation prediction score based on 24-hours electrocardiogram-monitoring data
Doctor G. Galati (Milan, IT)
Abstract Slides
Presentation thumbnail
Is excessive epicardial fat volume in asymptomatic young adult subjects with normal calcium score the trigger for abnormal ECGs and arrhythmia?
Doctor A. Sabatini (Florence, IT)
Abstract Slides
Presentation thumbnail
Prevention of readmission in the acute setting for heart failure patients: an adapted protocol of levosimendan infusion in inpatient high-intensity cardiac rehabilitation
Doctor I. Cusmano (Milan, IT)
Abstract Slides
Presentation thumbnail
Enhanced external counterpulsation (EECP) as a strategy for left ventricular and microcirculatory improvement: independent of cardiac intervention
Doctor O. Handayani (Jakarta, ID)
Abstract Slides

Access the full session

Session thumbnail
Poster session (2)

The Event

Event poster

ESC Preventive Cardiology 2025

4 April 2025 09:00 CET
You may be interested in
thumbnail
Webinar
Personalised secondary prevention post-ACS: the role of biomarkers
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Optimal medical therapy for primary prevention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources